Su1521 - Preliminary Efficacy and Safety of Acetyl-Coa Carboxylase (ACC) Inhibitor GS-0976 in Patents with Compensated Cirrhosis due to NASH

Stephen A. Harrison; Mazen Noureddin; Robert Herring; Peter Ruane; B. Mccolgan; Macky Natha; Brian J. Kirby; Cara Nelson; Raúl Antonio Aguilar Vera; Catherine Jia; Mani Subramanian; Robert P. Myers; Michael S. Middleton; Claude B. Sirlin; Mark Fitch; Kelvin W. Li; Marc Hellerstein; Eric Lawitz

doi:10.1016/s0016-5085(18)33862-9

Related publications

Article2018

Preliminary efficacy and safety of acetyl-CoA carboxylase inhibitor GS-0976 in patients with compensated cirrhosis due to NASH

S. Harrison, Mazen Noureddin, Robert Herring, P. Ruane, B. Mccolgan, Barbara D. Kirby, Christian J. Nelson, Raul Aguilar Schall, C. Jia, Madhu Subramanian, R. Myers, Mark R. Middleton, Claude B. Sirlin, Mark Fitch, K. Li, Marc Hellerstein, Eric Lawitz

Article2023

Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate

Mohamad Dandan, Julia Han, Sabrina A Mann, Rachael Kim, Kelvin W. Li, Hussein Mohammed, Jen‐Chieh Chuang, Kaiyi Zhu, Andrew N. Billin, Ryan S. Huss, Chuhan Chung, Robert P. Myers, Marc Hellerstein

Article2018

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

Eric Lawitz, Angie Coste, Fred Poordad, Naim Alkhouri, Nicole Loo, B. Mccolgan, Jacqueline M. Tarrant, Tuan Nguyen, Ling Han, Chuhan Chung, Adrian S. Ray, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Michael S. Middleton, Claude B. Sirlin, Rohit Loomba, Edna Nyangau, Mark Fitch, Kelvin W. Li, Marc Hellerstein

Article2019

SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis

Eric Lawitz, Edward Gane, Peter Ruane, Robert Herring, Ziad Younes, Paul Y. Kwo, Jie Zhang, Catherine Jia, Jay Chuang, B. Mccolgan, Chuhan Chung, Mani Subramanian, Robert P. Myers, Michael S. Middleton, Kelvin W. Li, Marc Hellerstein, Mazen Noureddin, Stephen A. Harrison, Rohit Loomba

Article2022

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Vincent E. Gaillard, Anwaar Saeed, Brooke Wietharn, Hannah Hildebrand, Linda Y. Wu, Celina Ang, Thomas U. Marron, Arndt Weinmann, Peter R. Galle, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Pei‐Chang Lee,